Neuronetics, Inc. (STIM) AI Stock Analysis

Neuronetics, Inc. is a commercial-stage medical technology company that designs, develops, and markets products for neurohealth disorders in the United States and internationally. Its primary offering is the NeuroStar Advanced Therapy System, a non-invasive, non-systemic treatment for adult patients diagnosed with major depressive disorder. Administered in an office-based setting, the system uses transcranial magnetic stimulation to generate an MRI-strength pulsed magnetic field that targets specific brain regions associated with mood regulation. The company distributes products directly through an internal sales and customer support team, collaborating with psychiatrists and mental health professionals.

Revenue grew from $55.3M in FY2021 to $65.2M in FY2022, $71.3M in FY2023, and $74.9M in FY2024, before increasing 99.2% to $149.2M in FY2025. Between FY2020 and FY2025, revenue generated a compound annual growth rate of 24.8%. However, gross margin contracted from 78.9% in FY2021 to 48.5% in FY2025. Neuronetics reported annual net income of -$31.2M in FY2021, -$43.7M in FY2024, and -$39.0M in FY2025. Free cash flow was -$21.2M in FY2025. In the trailing twelve months ending June 30, 2026, revenue stood at $155.1M, with quarterly revenue rising 9.1% year-over-year and profit margin at -19.6%.

As of June 30, 2026, Neuronetics held $19.4M in cash and short-term investments compared to total debt of $86.5M, leaving net debt at $67.1M. Shareholders' equity was $17.9M, resulting in a debt-to-equity ratio of 4.85, while total assets were $131.5M and the current ratio was 1.88. Operating cash flow in FY2025 was -$20.4M. Capital expenditures totaled $801,000, share buybacks were $1.7M, and the 5-year share count increased 170.6%.

At its last close of $1.89 on October 16, 2026, Neuronetics had a market capitalization of $143.6M and an enterprise value of $288.1M. The stock traded at a price-to-sales ratio of 0.9x and an enterprise value-to-revenue ratio of 1.9x, below the 4.1x price-to-sales median of its US-listed Healthcare peers. Its price-to-book ratio was 12.4x. Over the 1-year period, the stock fell 34.5%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock dropped 61.2% versus an 83.0% return for the benchmark index.

Wall Street coverage includes 3 Strong Buy ratings, 1 Buy rating, and zero Hold, Sell, or Strong Sell ratings. The mean price target is $5.75, which is 205.0% above the last close of $1.89. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $162.0M and EPS of -$0.47. For the next fiscal year, 1 analyst forecasts revenue of $177.0M and EPS of -$0.34. Neuronetics beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of Neuronetics, Inc. (STIM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: STIM income statement, STIM balance sheet, STIM key metrics, STIM analyst forecast, STIM chart. See the STIM stock overview for the latest quote and news.